Drugs / ICVB-1042
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05904236 | Jun 2023 → Dec 2024 | — | IconOVir Bio | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-11-10 | IconOVir Bio | Results IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022 iconovir.com ↗ |
| 2021-05-20 | IconOVir Bio | Results IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042 iconovir.com ↗
IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced new preclinical data demonstrating proof-of-concept for a proprietary combination of two selectivity mutations, made to Adenovirus (Ad) proteins E1A and E4-ORF6/7, both of which are incorporated into its rationally designed OV product candidates. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICVB-1042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05904236 ↗ |
| Route | Intravenous | “ICVB-1042 administered intravenously” NCT05904236 ↗ |